HER2-mutant non-small cell lung cancer (NSCLC) is a distinct molecular subtype of lung cancer that requires specific diagnostic testing and may benefit from targeted treatment approaches. This FAQ addresses common questions from healthcare professionals regarding HER2 alterations, biomarker testing, treatment strategies, and guideline recommendations.
HER2-mutant NSCLC is a subtype of non-small cell lung cancer characterised by alterations in the human epidermal growth factor receptor 2 (HER2/ERBB2) gene. These genetic changes can drive tumour growth and disease progression.
HER2 alterations in NSCLC may occur as:
Among these, HER2 mutations represent a distinct molecular driver that can influence treatment selection and clinical outcomes.
HER2 alterations are relatively uncommon compared with other actionable biomarkers in NSCLC. However, identifying these alterations is clinically important because they may help guide targeted treatment decisions and clinical trial eligibility. Healthcare professionals should consider comprehensive biomarker testing in patients with advanced disease whenever appropriate.
Although often discussed together, these represent different biological alterations:
A change in the HER2 gene sequence that can drive cancer growth.
An increase in the number of HER2 gene copies within tumour cells.
An increased amount of HER2 protein present on the tumour cell surface.
These alterations may have different diagnostic methods, clinical implications, and treatment considerations. Accurate identification of the specific alteration is therefore important.
Several testing methods may be used to identify HER2 alterations:
NGS is commonly used to detect HER2 mutations and evaluate multiple biomarkers simultaneously.
Tumour tissue can be analysed to identify genomic alterations and assess HER2 status.
Analysis of circulating tumour DNA from blood samples may provide additional genomic information when tissue is limited or unavailable.
Testing strategies should be aligned with institutional practice and current clinical guideline recommendations.
HER2 testing should be considered as part of comprehensive molecular profiling in patients with advanced NSCLC. Early identification of actionable alterations can help inform treatment decisions and potential eligibility for targeted therapies or clinical trials. Current discussions within clinical guidelines emphasise the importance of broad biomarker testing at diagnosis of advanced disease.
Treatment approaches may include:
Initial treatment selection depends on multiple clinical factors, including tumour characteristics, biomarker profile, disease burden, and patient-specific considerations.
Targeted therapies directed at HER2 have emerged as an important treatment option for patients with HER2-mutant NSCLC.
Following disease progression, treatment options may include HER2-targeted approaches, standard systemic therapies, and clinical trial participation where appropriate.
Current guideline discussions focus on:
Guideline recommendations continue to evolve as new evidence emerges and additional therapies become available.
Research in HER2-mutant NSCLC remains active. Current areas of investigation include:
Clinical trial participation remains an important consideration for eligible patients.
Treatment sequencing should be individualised based on:
Reassessment of disease and review of treatment goals are important components of ongoing management.
